Status: Recruiting
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Participants needed: 102
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)Updated: Apr 7, 2023Locations: 50
Eligibility criteria
Adults ≥ 18 years of age who are willing and able to provide written informed co... [+8]
Primary CNS lymphoma or active secondary CNS involvement and/or lymphomatous men... [+7]